K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
Hyeong Jung Woo,Seung-Hoon Kim,Hyo Jung Kang,Soo-Hwan Lee,Seung Joon Lee,Jong Man Kim,Ogan Gurel,Soo Yeol Kim,Hye Ran Roh,Jungmin Lee,Hyun-Young Shin,Yong-Il Shin,Sun Min Lee,Young Zoon Kim,Jung-Il Chae,Seo Young Lee,Min Hee Hong,Byoung Chul Cho,Eun Sook Lee,Klaus Pantel,Hye Ryun Kim,Minseok Kim +21 more
TL;DR: The full capture of heterogeneous CTC populations using fully automated, negative depletion-based continuous centrifugal microfluidics (CCM) is reported, enabling a more comprehensive application of robust CTC analysis in clinical practice.
Journal ArticleDOI
The DETECT study concept: Individualized therapy of metastatic breast cancer.
Arkadius Polasik,A Schramm,Thomas W. P. Friedl,Brigitte Rack,Elisabeth Trapp,Peter A. Fasching,Florin-Andrei Taran,Andreas D. Hartkopf,Andreas Schneeweiss,Volkmar Mueller,Bahriye Aktas,Klaus Pantel,Franziska Meier-Stiegen,Pauline Wimberger,Wolfgang Janni,Tanja Fehm +15 more
TL;DR: The importance of CTC phenotypes for guiding therapeutic decisions will be investigated within the DETECT studies, a prospective, multicenter, open-label clinical trial program comprising two phase III studies and one phase II study.
Journal ArticleDOI
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Fabienne Schochter,Brigitte Rack,Marie Tzschaschel,Arkadius Polasik,Ulrich Andergassen,Elisabeth Trapp,Marianna Alunni-Fabbroni,Andreas Schneeweiss,Volkmar Müller,Klaus Pantel,Jorg Gade,Ralf Lorenz,Mahdi Rezai,Hans Tesch,Ulrike Soeling,Tanja Fehm,Sven Mahner,Christian Schindlbeck,Werner Lichtenegger,Matthias W. Beckmann,Peter A. Fasching,Wolfgang Janni,Thomas W. P. Friedl +22 more
TL;DR: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens.
Journal ArticleDOI
Liquid biopsy: from discovery to clinical implementation
Proceedings ArticleDOI
Persistence of isolated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis.
Bjørn Naume,Tanja Fehm,Gro Wiedswang,Julia Jückstock,Elin Borgen,Brigitte Rack,M Synnestvedt,Stephan Braun,Harald Sommer,E Solomayer,Klaus Pantel,Klaus Friese,Wolfgang Janni +12 more
TL;DR: Evaluated whether the persistence of DTC after adjuvant therapy confers a risk for relapse and breast cancer-related death, and detected DTC in the BM in 15.5% of the pts.